{
    "clinical_study": {
        "@rank": "57015", 
        "arm_group": {
            "arm_group_label": "Treatment Period", 
            "arm_group_type": "Experimental", 
            "description": "200mg of lumacaftor every 12 hours in combination with 250mg of ivacaftor every 12 hours for 14 days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics and safety of lumacaftor in\n      combination with ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the\n      F508del-mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene."
        }, 
        "brief_title": "Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects 6 to 11 Years of Age With F508del-CFTR Mutation", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of CF with 2 CF-causing mutations and chronic sinopulmonary\n             disease or gastrointestinal/nutritional abnormalities\n\n          -  Subjects who weigh > 15 kg without shoes at Screening Visit\n\n          -  Subjects who are homozygous for the F508del-CFTR mutation\n\n          -  Forced expiratory volume in 1 second (FEV1) of 70% to 105% (inclusive) of predicted\n             normal for age, gender, and height (Knudson standards) at Screening\n\n          -  Subjects with stable CF disease and who are willing to remain on stable CF medication\n             regimen\n\n          -  Able to swallow tablets\n\n        Exclusion Criteria:\n\n          -  History of any illness or condition that might confound the results of the study or\n             pose an additional risk in administering study drug to the subject\n\n          -  Acute respiratory infection, pulmonary exacerbation, or changes in therapy for\n             pulmonary disease within 28 days before Day 1 of the study\n\n          -  Abnormal liver function as defined in the protocol at Screening\n\n          -  Abnormal renal function as defined in the protocol at Screening\n\n          -  History of solid organ or hematological transplantation\n\n          -  Ongoing participation in another therapeutic clinical study or prior participation in\n             an investigational drug study within 30 days prior to Screening\n\n          -  Evidence of lens opacity or cataract at the Screening\n\n          -  Colonization with organisms associated with a more rapid decline in pulmonary status\n             at Screening\n\n          -  A standard 12-lead ECG demonstrating QtcF >450 msec at Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897233", 
            "org_study_id": "VX13-809-011"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment Period", 
                "intervention_name": "Lumacaftor", 
                "intervention_type": "Drug", 
                "other_name": "VX-809"
            }, 
            {
                "arm_group_label": "Treatment Period", 
                "intervention_name": "Ivacaftor", 
                "intervention_type": "Drug", 
                "other_name": "VX-770"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Lumacaftor and ivacaftor PK parameters, including Cmax and AUC", 
            "safety_issue": "No", 
            "time_frame": "up to 14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897233"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Lumacaftor and ivacaftor metabolite PK parameters including Cmax and AUC", 
                "safety_issue": "No", 
                "time_frame": "up  to 14 days"
            }, 
            {
                "measure": "Safety and tolerability of lumacaftor in combination with ivacaftor as determined by clinical laboratory values, standard 12-lead electrocardiogram, vital signs, pulse oximetry, spirometry, and adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 days"
            }
        ], 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}